Year |
Citation |
Score |
2023 |
Salmaso V, Persico M, Da Ros T, Spalluto G, Kachler S, Klotz KN, Moro S, Federico S. Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for the Pan-Recognition of Human Adenosine Receptors. Biomolecules. 13. PMID 38002292 DOI: 10.3390/biom13111610 |
0.451 |
|
2023 |
Federico S, Persico M, Trevisan L, Biasinutto C, Bolcato G, Salmaso V, Da Ros T, Gianferrara T, Prencipe F, Kachler S, Klotz KN, Pacor S, Moro S, Spalluto G. [1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines. Chemmedchem. e202300299. PMID 37675643 DOI: 10.1002/cmdc.202300299 |
0.417 |
|
2023 |
Spinaci A, Buccioni M, Catarzi D, Cui C, Colotta V, Dal Ben D, Cescon E, Francucci B, Grieco I, Lambertucci C, Marucci G, Bassani D, Pavan M, Varano F, Federico S, ... Spalluto G, et al. "Dual Anta-Inhibitors" of the A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies. Pharmaceuticals (Basel, Switzerland). 16. PMID 37259317 DOI: 10.3390/ph16020167 |
0.394 |
|
2023 |
Gianferrara T, Pavan M, Bassani D, Vincenzi F, Pasquini S, Bolcato G, Varani K, Spalluto G, Federico S, Moro S. Are Two Riboses Better Than One? The Case of the Recognition and Activation of Adenosine Receptors. Chemmedchem. e202300109. PMID 37114338 DOI: 10.1002/cmdc.202300109 |
0.37 |
|
2021 |
Federico S, Margiotta E, Moro S, Kachler S, Klotz KN, Spalluto G. Potent and selective A adenosine receptor antagonists bearing aminoesters as heterobifunctional moieties. Rsc Medicinal Chemistry. 12: 254-262. PMID 34046614 DOI: 10.1039/d0md00380h |
0.436 |
|
2020 |
Pineux F, Federico S, Klotz KN, Kachler S, Michiels C, Sturlese M, Prato M, Spalluto G, Moro S, Bonifazi D. Targeting G protein-coupled receptors with magnetic carbon nanotubes: The A3 adenosine receptor case. Chemmedchem. PMID 32706529 DOI: 10.1002/Cmdc.202000466 |
0.431 |
|
2019 |
Federico S, Margiotta E, Moro S, Kozma E, Gao ZG, Jacobson KA, Spalluto G. Conjugable A adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes. European Journal of Medicinal Chemistry. 111886. PMID 31787357 DOI: 10.1016/J.Ejmech.2019.111886 |
0.592 |
|
2019 |
Federico S, Lassiani L, Spalluto G. Chemical Probes for the Adenosine Receptors. Pharmaceuticals (Basel, Switzerland). 12. PMID 31726680 DOI: 10.3390/Ph12040168 |
0.455 |
|
2019 |
Tan A, Babak MV, Venkatesan G, Lim C, Klotz KN, Herr DR, Cheong SL, Federico S, Spalluto G, Ong WY, Chen YZ, Loo JSE, Pastorin G. Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer Therapy. Molecules (Basel, Switzerland). 24. PMID 31614517 DOI: 10.3390/Molecules24203661 |
0.488 |
|
2019 |
Federico S, Margiotta E, Paoletta S, Kachler S, Klotz KN, Jacobson KA, Pastorin G, Moro S, Spalluto G. Pyrazolo[4,3-][1,2,4]triazolo[1,5-]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example. Medchemcomm. 10: 1094-1108. PMID 31391881 DOI: 10.1039/C9Md00014C |
0.618 |
|
2019 |
Federico S, Spalluto G. Functionalized ligands targeting G protein-coupled adenosine receptors. Future Medicinal Chemistry. 11: 1673-1677. PMID 31317789 DOI: 10.4155/Fmc-2019-0133 |
0.397 |
|
2019 |
Cacciari B, Crepaldi P, Cheng CY, Bossi E, Spalluto G, Federico S, Jacobson KA, Cattaneo M. Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors. Medicinal Chemistry (Shariqah (United Arab Emirates)). PMID 30734681 DOI: 10.2174/1573406415666190208124534 |
0.445 |
|
2018 |
Federico S, Margiotta E, Salmaso V, Pastorin G, Kachler S, Klotz KN, Moro S, Spalluto G. [1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A adenosine receptor subtype. European Journal of Medicinal Chemistry. 157: 837-851. PMID 30144700 DOI: 10.1016/J.Ejmech.2018.08.042 |
0.555 |
|
2018 |
Cacciari B, Spalluto G, Federico S. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge? Mini Reviews in Medicinal Chemistry. 18: 1168-1174. PMID 29692248 DOI: 10.2174/1389557518666180423113051 |
0.502 |
|
2018 |
Shao YM, Ma X, Paira P, Tan A, Herr DR, Lim KL, Ng CH, Venkatesan G, Klotz KN, Federico S, Spalluto G, Cheong SL, Chen YZ, Pastorin G. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment. Plos One. 13: e0188212. PMID 29304113 DOI: 10.1371/Journal.Pone.0188212 |
0.424 |
|
2016 |
Redenti S, Ciancetta A, Pastorin G, Cacciari B, Moro S, Spalluto G, Federico S. Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists. Current Topics in Medicinal Chemistry. PMID 27150365 DOI: 10.2174/1568026616666160506145831 |
0.578 |
|
2016 |
Federico S, Ciancetta A, Porta N, Redenti S, Pastorin G, Cacciari B, Klotz KN, Moro S, Spalluto G. 5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors. European Journal of Medicinal Chemistry. 108: 529-41. PMID 26717203 DOI: 10.1016/J.Ejmech.2015.12.019 |
0.48 |
|
2015 |
Federico S, Redenti S, Sturlese M, Ciancetta A, Kachler S, Klotz KN, Cacciari B, Moro S, Spalluto G. The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives. Plos One. 10: e0143504. PMID 26625265 DOI: 10.1371/Journal.Pone.0143504 |
0.479 |
|
2015 |
Ciancetta A, Sabbadin D, Federico S, Spalluto G, Moro S. Advances in Computational Techniques to Study GPCR-Ligand Recognition. Trends in Pharmacological Sciences. 36: 878-90. PMID 26538318 DOI: 10.1016/J.Tips.2015.08.006 |
0.336 |
|
2015 |
Venkatesan G, Paira P, Cheong SL, Federico S, Klotz KN, Spalluto G, Pastorin G. A facile and novel synthesis of N(2)-, C(6)-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists. European Journal of Medicinal Chemistry. 92: 784-98. PMID 25633494 DOI: 10.1016/J.Ejmech.2015.01.046 |
0.532 |
|
2014 |
Federico S, Ciancetta A, Porta N, Redenti S, Pastorin G, Cacciari B, Klotz KN, Moro S, Spalluto G. Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5- c ]pyrimidines to explore the antagonist profiling on adenosine receptors: A preliminary structure-activity relationship study Journal of Medicinal Chemistry. 57: 6210-6225. PMID 24972108 DOI: 10.1021/Jm500752H |
0.493 |
|
2014 |
Venkatesan G, Paira P, Cheong SL, Vamsikrishna K, Federico S, Klotz KN, Spalluto G, Pastorin G. Discovery of simplified N²-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: efficient synthetic approaches, biological evaluations and molecular docking studies. Bioorganic & Medicinal Chemistry. 22: 1751-65. PMID 24518296 DOI: 10.1016/J.Bmc.2014.01.018 |
0.541 |
|
2013 |
Dal Ben D, Buccioni M, Lambertucci C, Thomas A, Klotz KN, Federico S, Cacciari B, Spalluto G, Volpini R. 8-(2-Furyl)adenine derivatives as A₂A adenosine receptor ligands. European Journal of Medicinal Chemistry. 70: 525-35. PMID 24189496 DOI: 10.1016/J.Ejmech.2013.10.006 |
0.555 |
|
2013 |
Bacilieri M, Ciancetta A, Paoletta S, Federico S, Cosconati S, Cacciari B, Taliani S, Da Settimo F, Novellino E, Klotz KN, Spalluto G, Moro S. Revisiting a receptor-based pharmacophore hypothesis for human A 2A adenosine receptor antagonists Journal of Chemical Information and Modeling. 53: 1620-1637. PMID 23705857 DOI: 10.1021/Ci300615U |
0.535 |
|
2013 |
Kozma E, Jayasekara PS, Squarcialupi L, Paoletta S, Moro S, Federico S, Spalluto G, Jacobson KA. Fluorescent ligands for adenosine receptors. Bioorganic & Medicinal Chemistry Letters. 23: 26-36. PMID 23200243 DOI: 10.1016/J.Bmcl.2012.10.112 |
0.493 |
|
2013 |
Cheong SL, Federico S, Venkatesan G, Mandel AL, Shao YM, Moro S, Spalluto G, Pastorin G. The A3 adenosine receptor as multifaceted therapeutic target: Pharmacology, medicinal chemistry, and in silico approaches Medicinal Research Reviews. 33: 235-335. PMID 22095687 DOI: 10.1002/Med.20254 |
0.5 |
|
2012 |
Federico S, Ciancetta A, Sabbadin D, Paoletta S, Pastorin G, Cacciari B, Klotz KN, Moro S, Spalluto G. Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human A3 adenosine receptor antagonists Journal of Medicinal Chemistry. 55: 9654-9668. PMID 23098605 DOI: 10.1021/Jm300899Q |
0.54 |
|
2012 |
Federico S, Spalluto G. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands. Expert Opinion On Therapeutic Patents. 22: 369-90. PMID 22435652 DOI: 10.1517/13543776.2012.669375 |
0.518 |
|
2012 |
Kozma E, Kumar TS, Federico S, Phan K, Balasubramanian R, Gao ZG, Paoletta S, Moro S, Spalluto G, Jacobson KA. Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry. Biochemical Pharmacology. 83: 1552-61. PMID 22402302 DOI: 10.1016/J.Bcp.2012.02.019 |
0.557 |
|
2012 |
Dalpiaz A, Cacciari B, Vicentini CB, Bortolotti F, Spalluto G, Federico S, Pavan B, Vincenzi F, Borea PA, Varani K. A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approach. Molecular Pharmaceutics. 9: 591-604. PMID 22292533 DOI: 10.1021/Mp200489D |
0.447 |
|
2012 |
Lambertucci C, Buccioni M, Cacciari B, Dal Ben D, Federico S, Klotz K, Marucci G, Volpini R, Spalluto G, Cristalli G. ChemInform Abstract: New 9-Methyl-8-(4-hydroxyphenyl)adenine Derivatives as A1Adenosine Receptor Antagonists. Cheminform. 43: no-no. DOI: 10.1002/CHIN.201211150 |
0.345 |
|
2011 |
Cheong SL, Venkatesan G, Paira P, Jothibasu R, Mandel AL, Federico S, Spalluto G, Pastorin G. Pyrazolo derivatives as potent adenosine receptor antagonists: an overview on the structure-activity relationships. International Journal of Medicinal Chemistry. 2011: 480652. PMID 25954519 DOI: 10.1155/2011/480652 |
0.466 |
|
2011 |
Cheong SL, Dolzhenko AV, Paoletta S, Lee EPR, Kachler S, Federico S, Klotz KN, Spalluto G, Moro S, Pastorin G. Does the combination of optimal substitutions at the C 2-, N 5- and N 8-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A 3 adenosine receptors? Bioorganic and Medicinal Chemistry. 19: 6120-6134. PMID 21908194 DOI: 10.1016/J.Bmc.2011.08.026 |
0.477 |
|
2011 |
Cheong SL, Federico S, Venkatesan G, Paira P, Shao YM, Spalluto G, Yap CW, Pastorin G. Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 21: 2898-905. PMID 21511471 DOI: 10.1016/J.Bmcl.2011.03.073 |
0.524 |
|
2011 |
Federico S, Paoletta S, Cheong SL, Pastorin G, Cacciari B, Stragliotto S, Klotz KN, Siegel J, Gao ZG, Jacobson KA, Moro S, Spalluto G. Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility. Journal of Medicinal Chemistry. 54: 877-89. PMID 21214204 DOI: 10.1021/Jm101349U |
0.611 |
|
2011 |
Baraldi PG, Makaeva R, Pavani MG, Nuñez MdC, Spalluto G, Moro S, Falzoni S, Virgilio FD, Romagnoli R. Synthesis, biological activity and molecular modeling studies of 1,2,3,4-tetrahydroisoquinoline derivatives as conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor containing a tyrosine moiety. Drug Research. 52: 273-285. PMID 12040970 DOI: 10.1055/S-0031-1299891 |
0.519 |
|
2011 |
Baraldi PG, Cacciari B, Romagnoli R, Spalluto G. 1H-pyrazolo[2,3-d][1,2,4]triazine-3,7-diones as a new class of human leukocyte elastase inhibitors. Drug Research. 49: 997-1000. PMID 10635444 DOI: 10.1055/S-0031-1300540 |
0.326 |
|
2011 |
Lambertucci C, Buccioni M, Cacciari B, Ben DD, Federico S, Klotz K, Marucci G, Volpini R, Spalluto G, Cristalli G. New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A 1 adenosine receptor antagonists Collection of Czechoslovak Chemical Communications. 76: 1379-1393. DOI: 10.1135/Cccc2011091 |
0.549 |
|
2010 |
Paoletta S, Federico S, Spalluto G, Moro S. Receptor-driven identification of novel human A₃ adenosine receptor antagonists as potential therapeutic agents. Methods in Enzymology. 485: 225-44. PMID 21050920 DOI: 10.1016/B978-0-12-381296-4.00013-0 |
0.485 |
|
2010 |
Cheong SL, Dolzhenko A, Kachler S, Paoletta S, Federico S, Cacciari B, Dolzhenko A, Klotz KN, Moro S, Spalluto G, Pastorin G. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition. Journal of Medicinal Chemistry. 53: 3361-75. PMID 20307065 DOI: 10.1021/Jm100049F |
0.574 |
|
2010 |
Pastorin G, Federico S, Paoletta S, Corradino M, Cateni F, Cacciari B, Klotz KN, Gao ZG, Jacobson KA, Spalluto G, Moro S. Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. Bioorganic & Medicinal Chemistry. 18: 2524-36. PMID 20304654 DOI: 10.1016/J.Bmc.2010.02.039 |
0.624 |
|
2010 |
BARALDI PG, CACCIARI B, SPALLUTO G, PINEDA DE LAS INFANTS MJ, ZOCCHI C, FERRARA S, DIONISOTTI S. ChemInform Abstract: 1,2,3-Triazolo(5,4-e)1,2,4-triazolo(1,5-c)pyrimidine Derivatives: A New Class of A2A Adenosine Receptor Antagonists. Cheminform. 27: no-no. DOI: 10.1002/CHIN.199637217 |
0.364 |
|
2010 |
BARALDI PG, CACCIARI B, SPALLUTO G, JI X, OLAH ME, STILES G, DIONISOTTI S, ZOCCHI C, ONGINI E, JACOBSON KA. ChemInform Abstract: Novel N6-(Substituted-phenylcarbamoyl)adenosine-5′-uronamides as Potent Agonists for A3 Adenosine Receptors. Cheminform. 27: no-no. DOI: 10.1002/CHIN.199621237 |
0.563 |
|
2009 |
Morizzo E, Federico S, Spalluto G, Moro S. Human A3 adenosine receptor as versatile G protein-coupled receptor example to validate the receptor homology modeling technology. Current Pharmaceutical Design. 15: 4069-84. PMID 20028322 DOI: 10.2174/138161209789824777 |
0.495 |
|
2009 |
Michielan L, Stephanie F, Terfloth L, Hristozov D, Cacciari B, Klotz KN, Spalluto G, Gasteiger J, Moro S. Exploring potency and selectivity receptor antagonist profiles using a multilabel classification approach: the human adenosine receptors as a key study. Journal of Chemical Information and Modeling. 49: 2820-36. PMID 19908874 DOI: 10.1021/Ci900311J |
0.51 |
|
2009 |
Michielan L, Bolcato C, Federico S, Cacciari B, Bacilieri M, Klotz KN, Kachler S, Pastorin G, Cardin R, Sperduti A, Spalluto G, Moro S. Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites. Bioorganic & Medicinal Chemistry. 17: 5259-74. PMID 19501513 DOI: 10.1016/J.Bmc.2009.05.038 |
0.488 |
|
2009 |
Crepaldi P, Cacciari B, Bonache MC, Spalluto G, Varani K, Borea PA, Kügelgen Iv, Hoffmann K, Pugliano M, Razzari C, Cattaneo M. 6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors. Bioorganic & Medicinal Chemistry. 17: 4612-21. PMID 19464902 DOI: 10.1016/J.Bmc.2009.04.061 |
0.474 |
|
2008 |
Bolcato C, Cusan C, Pastorin G, Spalluto G, Cacciari B, Klotz KN, Morizzo E, Moro S. Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes. Purinergic Signalling. 4: 39-46. PMID 18368532 DOI: 10.1007/S11302-007-9058-Y |
0.535 |
|
2008 |
Michielan L, Bacilieri M, Schiesaro A, Bolcato C, Pastorin G, Spalluto G, Cacciari B, Klotz KN, Kaseda C, Moro S. Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptor. Journal of Chemical Information and Modeling. 48: 350-63. PMID 18215030 DOI: 10.1021/Ci700300W |
0.47 |
|
2007 |
Lambertucci C, Cristalli G, Dal Ben D, Kachare DD, Bolcato C, Klotz KN, Spalluto G, Volpini R. New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. Purinergic Signalling. 3: 339-46. PMID 18404447 DOI: 10.1007/S11302-007-9068-9 |
0.547 |
|
2007 |
Cacciari B, Bolcato C, Spalluto G, Klotz KN, Bacilieri M, Deflorian F, Moro S. Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile. Purinergic Signalling. 3: 183-93. PMID 18404432 DOI: 10.1007/S11302-006-9027-X |
0.539 |
|
2007 |
Cristalli G, Cacciari B, Dal Ben D, Lambertucci C, Moro S, Spalluto G, Volpini R. Highlights on the development of A(2A) adenosine receptor agonists and antagonists. Chemmedchem. 2: 260-81. PMID 17177231 DOI: 10.1002/Cmdc.200600193 |
0.523 |
|
2007 |
Bacilieri M, Kaseda C, Spalluto G, Moro S. Response Surface Analysis as Alternative 3D-QSAR Tool: Human A3 Adenosine Receptor Antagonists as a Key Study Letters in Drug Design & Discovery. 4: 122-127. DOI: 10.2174/157018007779422460 |
0.452 |
|
2006 |
Moro S, Deflorian F, Bacilieri M, Spalluto G. Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity. Current Pharmaceutical Design. 12: 2175-85. PMID 16796562 DOI: 10.2174/138161206777585265 |
0.462 |
|
2006 |
Moro S, Bacilieri M, Cacciari B, Bolcato C, Cusan C, Pastorin G, Klotz KN, Spalluto G. The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: application to a lead optimization of a human A3 adenosine receptor antagonist. Bioorganic & Medicinal Chemistry. 14: 4923-32. PMID 16564691 DOI: 10.1016/J.Bmc.2006.03.010 |
0.484 |
|
2006 |
Moro S, Deflorian F, Bacilieri M, Spalluto G. Novel strategies for the design of new potent and selective human A3 receptor antagonists: an update. Current Medicinal Chemistry. 13: 639-45. PMID 16529556 DOI: 10.2174/092986706776055670 |
0.415 |
|
2006 |
Pastorin G, Ros TD, Bolcato C, Montopoli C, Moro S, Cacciari B, Baraldi PG, Varani K, Borea PA, Spalluto G. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations. Journal of Medicinal Chemistry. 49: 1720-1729. PMID 16509587 DOI: 10.1021/Jm051147+ |
0.544 |
|
2006 |
Moro S, Bacilieri M, Ferrari C, Spalluto G. Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as alternative attractive tool to generate ligand-based 3D-QSARs. Current Drug Discovery Technologies. 2: 13-21. PMID 16472237 DOI: 10.2174/1570163053175439 |
0.418 |
|
2006 |
Pugliese AM, Coppi E, Spalluto G, Corradetti R, Pedata F. A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro. British Journal of Pharmacology. 147: 524-32. PMID 16415905 DOI: 10.1038/Sj.Bjp.0706646 |
0.404 |
|
2006 |
Moro S, Gao ZG, Jacobson KA, Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Medicinal Research Reviews. 26: 131-59. PMID 16380972 DOI: 10.1002/Med.20048 |
0.626 |
|
2006 |
Moro S, Bacilieri M, Deflorian F, Spalluto G. G protein-coupled receptors as challenging druggable targets: insights from in silico studies New Journal of Chemistry. 30: 301. DOI: 10.1039/B516389G |
0.482 |
|
2005 |
Cacciari B, Pastorin G, Bolcato C, Spalluto G, Bacilieri M, Moro S. A2B Adenosine Receptor Antagonists: Recent Developments Mini-Reviews in Medicinal Chemistry. 5: 1053-1060. PMID 16375751 DOI: 10.2174/138955705774933374 |
0.427 |
|
2005 |
Moro S, Bacilieri M, Cacciari B, Spalluto G. Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as new strategy for the prediction of the activity of human A(3) adenosine receptor antagonists. Journal of Medicinal Chemistry. 48: 5698-704. PMID 16134938 DOI: 10.1021/Jm0502440 |
0.439 |
|
2005 |
Pastorin G, Bolcato C, Cacciari B, Kachler S, Klotz K-, Montopoli C, Moro S, Spalluto G. Synthesis, biological and modeling studies of 1,3-di-n-propyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as adenosine receptor antagonists Farmaco. 60: 643-651. PMID 15961085 DOI: 10.1002/CHIN.200601220 |
0.556 |
|
2005 |
Cusan C, Spalluto G, Prato M, Adams M, Bodensieck A, Bauer R, Tubaro A, Bernardi P, Ros TD. Synthesis and biological evaluation of a new class of acyl derivatives of 3-amino-1-phenyl-4,5-dihydro-1H-pyrazol-5-one as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors. Farmaco. 60: 327-332. PMID 15848208 DOI: 10.1016/J.Farmac.2004.12.009 |
0.337 |
|
2005 |
Pastorin G, Bolcato C, Cacciari B, Kachler S, Klotz K, Montopoli C, Moro S, Spalluto G. Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists Farmaco. 60: 299-306. PMID 15848204 DOI: 10.1016/J.Farmac.2005.01.008 |
0.552 |
|
2005 |
Cusan C, Spalluto G, Prato M, Adams M, Bodensieck A, Bauer R, Tubaro A, Bernardi P, Ros TD. Synthesis and biological evaluation of new phenidone analogues as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors. Farmaco. 60: 7-13. PMID 15652362 DOI: 10.1016/J.Farmac.2004.09.002 |
0.327 |
|
2005 |
Cacciari B, Spalluto G. Non peptidic alphavbeta3 antagonists: recent developments. Current Medicinal Chemistry. 12: 51-70. PMID 15638730 DOI: 10.2174/0929867053363522 |
0.379 |
|
2005 |
Moro S, Braiuca P, Deflorian F, Ferrari C, Pastorin G, Cacciari B, Baraldi PG, Varani K, Borea PA, Spalluto G. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study. Journal of Medicinal Chemistry. 48: 152-62. PMID 15634009 DOI: 10.1021/Jm049662F |
0.49 |
|
2005 |
Moro S, Spalluto G, Jacobson KA. Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. Trends in Pharmacological Sciences. 26: 44-51. PMID 15629204 DOI: 10.1016/J.Tips.2004.11.006 |
0.564 |
|
2005 |
Cacciari B, Pastorin G, Moro S, Spalluto G. Potent and Selective A2A Adenosine Receptor Antagonists: Recent Improvement Frontiers in Medicinal Chemistry - Online. 2: 49-62. DOI: 10.2174/1567204052931069 |
0.497 |
|
2003 |
Moro S, Deflorian F, Spalluto G, Pastorin G, Cacciari B, Kim SK, Jacobson KA. Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. Chemical Communications (Cambridge, England). 2949-56. PMID 14703805 DOI: 10.1039/B303439A |
0.6 |
|
2003 |
Pastorin G, Ros TD, Spalluto G, Deflorian F, Moro S, Cacciari B, Baraldi PG, Gessi S, Varani K, Borea PA. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation. Journal of Medicinal Chemistry. 46: 4287-4296. PMID 13678407 DOI: 10.1021/Jm030852K |
0.49 |
|
2003 |
Cacciari B, Pastorin G, Spalluto G. Medicinal chemistry of A2A adenosine receptor antagonists. Current Topics in Medicinal Chemistry. 3: 403-11. PMID 12570758 DOI: 10.2174/1568026033392183 |
0.549 |
|
2003 |
Cacciari B, Spalluto G, Ferretti V. Synthesis of pyridazine derivatives through the unexpected intermediate 5-amino- 4-cyano -2,3-dihydro-furan-2,3-disulfonic acid disodium salt Journal of Heterocyclic Chemistry. 40: 1065-1069. DOI: 10.1002/CHIN.200420147 |
0.319 |
|
2002 |
Baraldi PG, Cacciari B, Borean PA, Varanin K, Pastorin G, Da Ros T, Tabrizi MA, Fruttarolo F, Spalluto G. Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes? Current Pharmaceutical Design. 8: 2299-332. PMID 12369947 DOI: 10.2174/1381612023392838 |
0.55 |
|
2002 |
Maconi A, Pastorin G, Da Ros T, Spalluto G, Gao ZG, Jacobson KA, Baraldi PG, Cacciari B, Varani K, Moro S, Borea PA. Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist. Journal of Medicinal Chemistry. 45: 3579-82. PMID 12166930 DOI: 10.1021/Jm020974X |
0.617 |
|
2002 |
Baraldi PG, Cacciari B, Moro S, Spalluto G, Pastorin G, Ros TD, Klotz K, Varani K, Gessi S, Borea PA. Synthesis, Biological Activity, and Molecular Modeling Investigation of New Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Human A3 Adenosine Receptor Antagonists Journal of Medicinal Chemistry. 45: 770-780. PMID 11831890 DOI: 10.1021/Jm0109614 |
0.555 |
|
2002 |
Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Monopoli A, Ongini E, Varani K, Borea PA. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. Journal of Medicinal Chemistry. 45: 115-26. PMID 11754583 DOI: 10.1021/Jm010924C |
0.511 |
|
2002 |
Da Ros T, Vázquez E, Spalluto G, Moro S, Boutorine A, Prato M. Design, synthesis and biological properties of fulleropyrrolidine derivatives as potential DNA photo-probes Journal of Supramolecular Chemistry. 2: 327-334. DOI: 10.1016/S1472-7862(03)00089-3 |
0.314 |
|
2002 |
Ros T, Bergamin M, Vázquez E, Spalluto G, Baiti B, Moro S, Boutorine A, Prato M. Synthesis and Molecular Modeling Studies of Fullerene−5,6,7-Trimethoxyindole−Oligonucleotide Conjugates as Possible Probes for Study of Photochemical Reactions in DNA Triple Helices European Journal of Organic Chemistry. 2002: 405-413. DOI: 10.1002/1099-0690(20022)2002:3<405::Aid-Ejoc405>3.0.Co;2-2 |
0.316 |
|
2002 |
Cusan C, Ros TD, Spalluto G, Foley S, Janot J, Seta P, Larroque C, Tomasini MC, Antonelli T, Ferraro L, Prato M. A New Multi‐Charged C60 Derivative: Synthesis and Biological Properties European Journal of Organic Chemistry. 2002: 2928-2934. DOI: 10.1002/1099-0690(200209)2002:17<2928::Aid-Ejoc2928>3.0.Co;2-I |
0.308 |
|
2001 |
Gessi S, Varani K, Merighi S, Morelli A, Ferrari D, Leung E, Baraldi PG, Spalluto G, Borea PA. Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells British Journal of Pharmacology. 134: 116-126. PMID 11522603 DOI: 10.1038/Sj.Bjp.0704254 |
0.44 |
|
2001 |
Baraldi PG, Cacciari B, Moro S, Romagnoli R, Ji Xd, Jacobson KA, Gessi S, Borea PA, Spalluto G. Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies. Journal of Medicinal Chemistry. 44: 2735-42. PMID 11495585 DOI: 10.1021/Jm010818A |
0.623 |
|
2001 |
Baraldi PG, Balboni G, Pavani MG, Spalluto G, Tabrizi MA, Clercq ED, Balzarini J, Bando T, Sugiyama H, Romagnoli R. Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders. Journal of Medicinal Chemistry. 44: 2536-43. PMID 11472207 DOI: 10.1021/Jm0108404 |
0.351 |
|
2001 |
Bergamin M, Ros TD, Spalluto G, Boutorine A, Prato M. Synthesis of a hybrid fullerene–trimethoxyindole–oligonucleotide conjugate Chemical Communications. 17-18. DOI: 10.1039/B008744K |
0.307 |
|
2001 |
Baraldi PG, Cacciari B, Romagnoli R, Klotz K, Spalluto G, Varani K, Gessi S, Merighi S, Borea PA. Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor ligands: A starting point for searching A2B adenosine receptor antagonists Drug Development Research. 53: 225-235. DOI: 10.1002/Ddr.1191 |
0.549 |
|
2001 |
Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Varani K, Gessi S, Merighi S, Borea PA. Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new pharmacological tool for the characterization of the human A3 adenosine receptor Drug Development Research. 52: 406-415. DOI: 10.1002/Ddr.1141 |
0.532 |
|
2000 |
Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Moro S, Klotz K, Leung E, Varani K, Gessi S, Merighi S, Borea PA. Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen. Journal of Medicinal Chemistry. 43: 4768-4780. PMID 11123985 DOI: 10.1021/Jm001047Y |
0.547 |
|
2000 |
Todde S, Moresco RM, Simonelli P, Baraldi PG, Cacciari B, Spalluto G, Varani K, Monopoli A, Matarrese M, Carpinelli A, Magni F, Kienle MG, Fazio F. Design, Radiosynthesis, and Biodistribution of a New Potent and Selective Ligand for in Vivo Imaging of the Adenosine A2A Receptor System Using Positron Emission Tomography Journal of Medicinal Chemistry. 43: 4359-4362. PMID 11087559 DOI: 10.1021/Jm0009843 |
0.4 |
|
2000 |
Baraldi PG, Cacciari B, Romagnoli R, Merighi S, Varani K, Borea PA, Spalluto G. A3 Adenosine Receptor Ligands: History and Perspectives Medicinal Research Reviews. 20: 103-128. PMID 10723024 DOI: 10.1002/(Sici)1098-1128(200003)20:2<103::Aid-Med1>3.0.Co;2-X |
0.525 |
|
2000 |
Baraldi PG, Cacciari B, Romagnoli R, Varani K, Merighi S, Gessi S, Borea PA, Leung E, Hickey SL, Spalluto G. Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors Bioorganic & Medicinal Chemistry Letters. 10: 209-211. PMID 10698437 DOI: 10.1016/S0960-894X(99)00674-5 |
0.455 |
|
2000 |
Baraldi PG, Spalluto G, Cacciari B, Romagnoli R. DNA minor groove alkylating agents structurally related to distamycin A Expert Opinion On Therapeutic Patents. 10: 891-904. DOI: 10.1517/13543776.10.6.891 |
0.309 |
|
2000 |
Cacciari B, Romagnoli R, Baraldi PG, Ros TD, Spalluto G. CC-1065 and the duocarmycins: recent developments Expert Opinion On Therapeutic Patents. 10: 1853-1871. DOI: 10.1517/13543776.10.12.1853 |
0.345 |
|
2000 |
Baraldi PG, Cacciari B, Romagnoli R, Varani K, Merighi S, Gessi S, Borea PA, Leung E, Hickey SL, Spalluto G. Corrigendum to “Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors”: (Biorg. Med. Chem. Lett. 2000, 10, 209–211) Bioorganic & Medicinal Chemistry Letters. 10. DOI: 10.1016/S0960-894X(00)00239-0 |
0.391 |
|
1999 |
Baraldi PG, Balboni G, Cacciari B, Guiotto A, Manfredini S, Romagnoli R, Spalluto G, Thurston DE, Howard PW, Bianchi N, Rutigliano C, Mischiati C, Gambari R. Synthesis, in vitro antiproliferative activity, and DNA-binding properties of hybrid molecules containing pyrrolo[2,1-c][1, 4]benzodiazepine and minor-groove-binding oligopyrrole carriers. Journal of Medicinal Chemistry. 42: 5131-5141. PMID 10602698 DOI: 10.1021/Jm991033W |
0.369 |
|
1999 |
Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Klotz K, Leung E, Varani K, Gessi S, Merighi S, Borea PA. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3 Adenosine Receptor Antagonists Journal of Medicinal Chemistry. 42: 4473-4478. PMID 10579811 DOI: 10.1021/Jm991114S |
0.512 |
|
1999 |
Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Boyce CW, Boger DL. Resolution of a CPzI precursor, synthesis and biological evaluation of (+) and (-)-N-Boc-CPzI: a further validation of the relationship between chemical solvolytic stability and cytotoxicity. Bioorganic & Medicinal Chemistry Letters. 9: 3087-92. PMID 10560730 DOI: 10.1016/S0960-894X(99)00533-8 |
0.309 |
|
1999 |
Baraldi PG, Cacciari B, Romagnoli R, Spalluto G. A1 and A3 adenosine receptor agonists: an overview Expert Opinion On Therapeutic Patents. 9: 515-527. DOI: 10.1517/13543776.9.5.515 |
0.339 |
|
1999 |
Bianchi N, Spalluto G, Cacciari B, Romagnoli R, Feriotto G, Mischiati C, Rutigliano C, Borsetti E, Baraldi PG, Gambari R. Selective binding to human genomic sequences of two synthetic analogues structurally related to U‐71184 and adozelesin Drug Development Research. 46: 96-106. DOI: 10.1002/(Sici)1098-2299(199902)46:2<96::Aid-Ddr2>3.0.Co;2-6 |
0.341 |
|
1999 |
Baraldi PG, Borea PA, Bergonzoni M, Cacciari B, Ongini E, Recanatini M, Spalluto G. Comparative molecular field analysis (CoMFA) of a series of selective adenosine receptor A2A antagonists Drug Development Research. 46: 126-133. DOI: 10.1002/(SICI)1098-2299(199902)46:2<126::AID-DDR5>3.0.CO;2-7 |
0.372 |
|
1998 |
Shryock JC, Snowdy S, Baraldi PG, Cacciari B, Spalluto G, Monopoli A, Ongini E, Baker SP, Belardinelli L. A2A-adenosine receptor reserve for coronary vasodilation. Circulation. 98: 711-8. PMID 9715864 DOI: 10.1161/01.Cir.98.7.711 |
0.389 |
|
1998 |
Baraldi PG, Cacciari B, Pineda de Las Infantas MJ, Romagnoli R, Spalluto G, Volpini R, Costanzi S, Vittori S, Cristalli G, Melman N, Park KS, Ji XD, Jacobson KA. Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists. Journal of Medicinal Chemistry. 41: 3174-85. PMID 9703463 DOI: 10.1021/Jm980147P |
0.621 |
|
1998 |
Baraldi PG, Cacciari B, Spalluto G, Bergonzoni M, Dionisotti S, Ongini E, Varani K, Borea PA. Design, Synthesis, and Biological Evaluation of a Second Generation of Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as Potent and Selective A2A Adenosine Receptor Antagonists Journal of Medicinal Chemistry. 41: 2126-2133. PMID 9622554 DOI: 10.1021/Jm9708689 |
0.524 |
|
1996 |
Baraldi PG, Cacciari B, Spalluto G, Villatoro MJPdlIy, Zocchi C, Dionisotti S, Ongini E. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives: Potent and Selective A2A Adenosine Antagonists Journal of Medicinal Chemistry. 39: 1164-1171. PMID 8676354 DOI: 10.1021/Jm950746L |
0.55 |
|
1996 |
Baraldi PG, Cacciari B, Spalluto G, Ji XD, Olah ME, Stiles G, Dionisotti S, Zocchi C, Ongini E, Jacobson KA. Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors. Journal of Medicinal Chemistry. 39: 802-6. PMID 8576924 DOI: 10.1021/Jm950518R |
0.599 |
|
1996 |
Barco A, Benetti S, Risi CD, Pollini GP, Spalluto G, Zanirato V. 4-Isopropyl-2-oxazolin-5-one anion as masked umpoled synthon for both formyl and hydroxycarbonyl anions: Generation, reactivity and synthetic applications Tetrahedron. 52: 4719-4734. DOI: 10.1016/0040-4020(96)00143-3 |
0.32 |
|
1996 |
Baraldi PG, Cacciari B, Dionisotti S, Egan J, Spalluto G, Zocchi C. Synthesis of the tritium labeled SCH 58261, a new non-xanthine A2A adenosine receptor antagonist Journal of Labelled Compounds and Radiopharmaceuticals. 38: 725-732. DOI: 10.1002/(SICI)1099-1344(199608)38:8<725::AID-JLCR885>3.0.CO;2-G |
0.375 |
|
1994 |
Barco A, Benetti S, Risi CD, Pollini GP, Romagnoli R, Spalluto G, Zanirato V. Enantioselective synthesis of (−)-meroquinene through tandem Michael reaction methodology. Tetrahedron. 50: 2583-2590. DOI: 10.1016/S0040-4020(01)86974-X |
0.336 |
|
1993 |
Baraldi PG, Bazzanini R, Bigoni A, Manfredini S, Simoni D, Spalluto G. An Efficient Synthesis of 4-Oxo-2,5-hexadienoates via Δ2-Isoxazoline Intermediates Synthesis. 1993: 1206-1208. DOI: 10.1055/S-1993-26023 |
0.364 |
|
Show low-probability matches. |